Compare BioNano Genomics Inc (BNGO) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Synchrony Financial — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Synchrony Financial trades at $78.37 (market cap $25.53B). The key difference: Synchrony Financial is far larger — about 1869× BioNano Genomics Inc's market cap, and Synchrony Financial pays a 1.73% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | SYF | |
|---|---|---|
Market Cap | $13.66M | $25.53B |
Sector | Health | Financials |
52-Week High | $4.92 | $88.47 |
52-Week Low | $1.06 | $63.78 |
Enterprise Value | $16.26M | — |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Synchrony Financial (SYF) trades at $79.41, up 1.56% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with a P/E of 8.05, net income margin of 23.4%, and consistent earnings beats in recent quarters. Recent Q2 2026 results showed $2.59 EPS, beating estimates by 24.5%, while the CareCredit partnership with Stripe expands financing access for health providers.
SYF presents attractive value with robust capital returns including aggressive buybacks and dividends. Analyst consensus is strongly bullish with a $86.33 price target representing 8.7% upside. Key risks include consumer credit deterioration and rising expenses, but stable purchase volume growth and improved net interest margin outlook support continued earnings growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
